This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Biotech Stocks Under $5 Moving Higher

Pluristem Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Pluristem Therapeutics (PSTI - Get Report) is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. This stock is trading up 12.5% to $4.72 in recent trading.

Today's Range: $4.51-$4.90

52-Week Range: $1.98-$5.00

Volume: 3 million

Three-Month Average Volume: 840,916

>>5 Technical Trades Under $5

Shares of PSTI are ripping higher today after the company said a third critically ill patient was successfully treated with its Placental eXpanded cells under compassionate use. The company said the outcome of its recent success with PLX cells suggest it may have significant potential to treat a range of indications of bone marrow diseases.

From a technical perspective, PSTI is gapping up big here with monster volume. This move is quickly pushing PSTI within range of triggering a major breakout trade. That trade will hit once PSTI takes out some near-term overhead resistance and its 52-week high at $5 with high volume.

Traders should now look for long-biased trades in PSTI once it sustains a move or close above $5 with volume that's near or above 840,916 shares. If that breakout triggers soon, then PSTI will have a great chance of hitting $6 to $7 in the near future. Traders should use $4.50 as near-term support if PSTI can hold this gap and potentially breakout soon. Any high-volume move below $4.50 could send PSTI back towards $4.25 to $4, before it possibly sets up again to attempt the breakout.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CDXS $5.08 0.00%
KERX $11.45 0.00%
OREX $7.54 0.00%
PSTI $2.81 0.00%
AAPL $124.75 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs